Prof. Dr.

Erkan Doğan

Bilimsel Yayınlar

1. Adem Yokuş, Harun Arslan, Zülküf Akdemir, İbrahim Akbudak, Necat Almalı, Çetin Kotan, Erkan Doğan. Measurement of Postoperative Liver Volume Changes In Patients With Gastric Cancer By Computed Tomography. East J Med 28(2):206-210, 2023. DOI:10.5505/ejm.2023.12129

2. Aycan A, Celik S, Kuyumcu F, Akyol ME, Arslan M, Dogan E, Arslan H. Spinal Metastasis of Unknown Primary Accompanied by Neurologic Deficit or Vertebral Instability. World Neurosurg. 2018 Jan;109:e33-e42. doi:10.1016/j.wneu.2017.09.099

3. Arslan H, Fatih Özbay M, Çallı İ, Doğan E, Çelik S, Batur A, Bora A, Yavuz A, Bulut MD, Özgökçe M, Çetin Kotan M. Contribution of diffusion weighted MRI to diagnosis and staging in gastric tumors and comparison with multi-detector computed tomography. Radiol Oncol. 2017;51(1):23-29

4. Sunnetcioglu A, Arısoy A, Demir Y, Ekin S, Dogan E. Associations between the standardized uptake value of 18F-FDG PET/CT and demographic, clinical, pathological, radiological factors in lung cancer. Int J Clin Exp Med. 2015;8(9):15794-800

5. Turan N, Benekli M, Unal OU, Unek İT, Tastekin D ve ark. Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma. Chin J Cancer Res. 2015;27(4):408-16

6. Can A, Dogan E, Bayoglu IV ve ark. Multicenter epidemiologic study on hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev. 2014;15(6):2923-7

7. Turan N, Benekli M, Dane F ve ark. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer. Thorac Cancer. 2014;5(5):398-404

8. Koca D, Dogan E, Yardim H ve ark. A modified DCF regimen as primary treatment for patients with metastatic gastric cancer. J BUON. 2013;18(2):377-84

9. Dogan E, Yorgun H, Petekkaya I ve ark. Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: A single center experience. Med Oncol. 2012

10. Dogan E, Yalcin S, Koca D, Olmez A. Clinicopathological characteristics of hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev. 2012;13:2985-90

11. Arslan C, Ozdemir E, Dogan E, Ozisik Y, Altundag K. Secondary hematological malignancies after treatment of non-metastatic breast cancer. J BUON. 2011;16:744-50

12. Dogan E, Aksoy S, Dizdar O ve ark. Pure mucinous carcinoma of the breast: a single center experience. J BUON. 2011;16:565-7

13. Bulut N, Aksoy S, Dizdar O ve ark. Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer. Med Oncol. 2011;28:S75-9

14. Turgut D, Kalan I, Dede DS, Dogan E, Altundag K. Ipsilateral axillary recurrence of breast cancer 22 years after primary surgery: the latest recurrence in the literature. J BUON. 2011;16:571

15. Kara O, Ozdemir E, Arslan C, Dogan E, Altundag K. Acute promyelocytic leukemia in a young patient with breast cancer. Med Oncol. 2011;28:249-50

16. Z. Arik, E. Dogan, S. Aksoy, K. Altundag. Long-term survivors among breast cancer patients with brain metastases. Ann Oncol. 2010;21:1128

17. E. Dogan, S. Aksoy, O. Dizdar, D.S. Dede, C. Arslan, Y. Ozisik, K. Altundag. Other malignancies in patients with breast cancer: a single institute experience. Med Oncol. 2010 Dec;27(4):1434-1435

18. E. Dogan, S. Aksoy, C. Arslan, D.S. Dede, K. Altundag. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. Med Oncol. 2010;27:1436-1437

19. E. Altan, C. Arslan, D. Dede, E. Dogan, K. Altundag. Primary angiosarcoma of the breast after pregnancy. Am Surg. 2010;76:E115

20. N. Kertmen, E. Dogan, K. Altundag. Pure mucinous breast carcinoma with lung metastasis in a young male patient. Am Surg. 2010;76:E146

21. D. Sarikaya, O. Varan, G. Ozen, E. Dogan, K. Altundag. Late recurrence of granulosa cell tumor of the ovary with synchronous gastric signet-ring cell carcinoma. J BUON. 2010;15:799-800

22. O. Varan, G. Ozen, D. Sarikaya, E. Dogan, K. Altundag. Malignant hypercalcemia in a patient with maxillary sinus squamous cell carcinoma without skeletal metastases. Am Surg. 2010;76:E9-10

23. E. Altan, B. Bitik, Y. Kalpakci, E. Dogan, K. Altundag. Probable hepatotoxicity related to Nerium oleander extract in a patient with metastatic synovial sarcoma of the knee. J Altern Complement Med. 2009;15:113

24. B. Bitik, Y. Kalpakci, E. Altan, E. Dogan, K. Altundag. Successful treatment of primary duodenal carcinoma with bilateral adrenal metastases with docetaxel-cisplatin-5-fluorouracil regimen. Ann Oncol. 2009;20:394-395

25. E. Dogan, R. Ozgur, V. Ercan, A. Tekin, O. Senkal, U. Cevikbas. Nodular regenerative hyperplasia of the liver: a case report. Turkish Journal of Gastroenterology. 2003;14:64

7.3. Uluslararası Bilimsel Toplantılarda Sunulan ve Bildiri Kitabında Basılan Bildiriler

1. E. Dogan, H. Yorgun, I. Petekkaya, N. Ozer, K. Altundag, Y. Ozisik. Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: A single center experience. 2011 ASCO Annual Meeting, April 2011, Chicago, USA. Sözel Bildiri

2. O. Keskin, C. Arslan, O. Dizdar, S. Aksoy, E. Dogan, D.S. Dede, I.H. Gullu, Y.Y. Ozisik, K. Altundag. Relation of tumor localization and metastasis sites in patients with breast cancer. ASCO 2011, Chicago, USA

3. D.S. Dede, C. Arslan, S. Aksoy, O. Dizdar, E. Dogan, A. Alkan, I.H. Gullu, Y.Y. Ozisik, K. Altundag. Clinicopathologic features of patients with breast cancer under treatment of bisphosphonate at the time of diagnosis: Retrospective analysis. ASCO 2011, Chicago, USA

4. I. Petekkaya, C. Arslan, E. Dogan, M. Solak, O. Keskin, N. Kertmen, Y.Y. Ozisik, K. Altundag. Body mass index in breast cancer subtypes. ASCO 2011, Chicago, USA

5. M. Solak, F.P. Turkoz, I. Petekkaya, C. Arslan, N. Kertmen, O. Keskin, E. Dogan, Y.Y. Ozisik, M.K. Altundag. Association between blood groups and breast cancer subtype. ASCO 2011, Chicago, USA

6. M. Ozen, S. Aksoy, O. Dizdar, D.S. Dede, E. Dogan, C. Arslan, I.H. Gullu, M.K. Altundag. Addition of nine weeks of trastuzumab to adjuvant chemotherapy in operable HER2-positive breast cancer patients: Retrospective analysis. ASCO 2010, Chicago, USA

7. Z.G. Sürmeli, S. Aksoy, O. Dizdar, D.S. Dede, E. Dogan, C. Arslan, I.H. Gullu, K. Altundag. Docetaxel/doxorubicin/cyclophosphamide chemotherapy for operable HER2-negative, node-positive breast cancer patients: Results from a single institution. ASCO 2010, Chicago, USA

8. S. Aksoy, C. Arslan, M. Kurt, O. Dizdar, D.S. Dede, E. Dogan, I.H. Gullu, Y.Y. Ozisik, M.K. Guler. Increased mean corpuscular volume of erythrocytes with capecitabine treatment in metastatic breast cancer patients: A marker of clinical benefit. ASCO 2010, Chicago, USA

9. C. Arslan, O. Dizdar, D.S. Dede, M. Isik, E. Dogan, Y.Y. Ozisik, K. Altundag. Clinicopathological features of locally advanced HER2-negative breast cancer patients with stage N3 disease. ASCO 2011, Chicago, USA

10. S. Aksoy, N. Bulut, O. Dizdar, D. Dede, C. Arslan, E. Dogan, Y. Ozisik, K. Altundag. Demographic, clinical and pathological characteristics of very young breast cancer patients younger than 30 years in Turkish population. 5th International APOCP Conference, 2010, Istanbul, Turkey

11. A. Can, E. Dogan, I.V. Bayoglu, A.M. Tatli, M. Besiroglu, M. Kocer, U. Uyetürk, D. Kivrak, Z. Orakci, O. Bal, T. Kacan, N. Turan. Epidemiology of Hepatocellular Carcinoma in Turkey: Outcome of a Multicenter Study. 3rd International Gastrointestinal Cancer Conference, December 13-15, 2013, Antalya, Turkey

12. E. Dogan, A. Can, M.F. Ozbay, H. Arslan, G. Yilmazer, D. Koca, C. Kotan. Clinicopathological Characteristics of Esophageal Cancer Patients of Van Region. 3rd International Gastrointestinal Cancer Conference, December 13-15, 2013, Antalya, Turkey

13. H. Arslan, M.F. Ozbay, I. Calli, E. Dogan. Comparison of Diffusion Weighted MR Imaging with Multidetector CT Imaging in the Diagnosis of Gastric Tumors. 3rd International Gastrointestinal Cancer Conference, December 13-15, 2013, Antalya, Turkey

14. E. Dogan, H. Guducuoglu, A. Can, R. Erten, S. Koc, Y. Bayram. Human Papilloma Virus and Survival of Patients with Esophageal Squamous Cell Cancers. 3rd International Gastrointestinal Cancer Conference, December 13-15, 2013, Antalya, Turkey

15. H.G. Sahin, G. Guvendi, H.A. Sahin, D. Kusaslan Avci, E. Dogan. Violence among Cancer Patients in Eastern Turkey. World Congress of Internal Medicine, October 25-29, 2014, Seoul, Korea. Oral Presentation

16. E. Dogan, A. Can. Comparison of palliative chemotherapy using cisplatin and fluorouracil with docetaxel, cisplatin and fluorouracil combination regimens in patients with metastatic esophageal cancer. 4th International Gastrointestinal Cancer Conference, December 2014. Oral Presentation

7.4. Uluslararası Dergilerde Yayımlanan Abstraktlar

1. Sarici F, Aksoy S, Dizdar O, Dede D, Arslan C, Dogan E, Ozkan C, Cinel M, Yaman S, Kizilarslan C, Ozisik Y, Altundag K. The frequency and determinants of metabolic syndrome in patients with operable stage I-III breast cancer. 7th Metabolic Syndrome Symposium, Antalya, Turkey, 29 April-2 May 2010. Obesity Reviews. 2010;11:482. Abstract no 35, Ref no 72. SCIE

2. Kizilarslanoglu C, Aksoy S, Dizdar O, Dede D, Arslan C, Dogan E, Ozisik Y, Altundag K. Prognostic significance of body mass index in breast cancer patients. 7th Metabolic Syndrome Symposium, Antalya, Turkey, 29 April-2 May 2010. Obesity Reviews. 2010;11:483. Abstract no 36, Ref no 73. SCIE

7.5. Ulusal Hakemli Dergilerde Yayınlanan Makaleler

1. S. Celik, E. Dogan, H. Arslan, A. Batur, R. Kiziltan, O. Toktas, O. Yilmaz, M.C. Kotan. Changing Trends and Experience with Esophageal Cancer Surgery in a Single University Hospital: Are the Results Similar or Not. Bagcilar Medical Bulletin. 2017;2(1):1-8

2. E. Dogan. Nonseminomatous Testicular Cancer. Turkiye Klinikleri Journal of Medical Oncology. 2015

3. G. Ugurluer, E. Dogan, N. Turan. Cutaneous Metastases from Transitional Cell Carcinoma of the Bladder in a Case with Two Primaries. Erciyes Medical Journal. 2010

4. E. Dogan, S. Kilickap, I. Celik. New Drugs Used in Chemoprevention. Review. Turkiye Klinikleri Journal of Medical Oncology Special Topics. 2009;73-82

5. A. Surardamar, T. Yakar, N. Usalan, E. Dogan, M.F. Akdogan, O. Yapici. Conn’s Syndrome: Case Report. Haydarpasa Numune Training and Research Hospital Medical Journal. 2003;115-118

6. E. Hur, N.Y. Bagatur, E. Ahishali, E. Dogan, O. Mavis. Comparison of Treatment Efficacy of Two-Week Lansoprazole plus One- and Two-Week Clarithromycin Combinations in Helicobacter Pylori Eradication. Taksim Training and Research Hospital Medical Journal. 2002;32:7-12

7. E. Hur, O. Mavis, E. Dogan, F. Akvardar, R. Ozgur, V. Ercan. Monoclonal Gammopathy of Undetermined Significance: A Case Report. Taksim Training and Research Hospital Medical Journal. 2002;32:13-16

8. E. Dogan, I. Ekizoglu, E. Hur, O. Mavis, V. Ercan, A. Tekin. Phenytoin-Induced Osteomalacia: A Case Report. Taksim Training and Research Hospital Medical Journal. 2002;32:20-22

14. Yer Aldığı Klinik Araştırmalar

1. Comparative analysis of patient satisfaction between public hospitals and private hospital outpatient clinics. Marmara University Department of Public Health, 1998. Advisor Prof. Dr. Osman Hayran. Unpublished Research Report

2. Coinvestigator in the international INVEST study

3. Coinvestigator in the international Cariatide study

4. Coinvestigator in the international CA163-140 study. Phase II Combination of Trastuzumab and Ixabepilone versus Trastuzumab and Docetaxel in Patients with Advanced and or Metastatic Breast Cancer

5. Coinvestigator in the international ATHENA study

6. Subinvestigator in the national ERADA study

7. Tide 13-14 Observational Phase IV Study. Principal Investigator

8. A Phase 3 Randomized Double Blind Place Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Adenocarcinoma. NCT0254504. Ongoing

Üyelikler

1. European Society of Medical Oncology ESMO

2. Türk Tıbbi Onkoloji Derneği TTOD

3. Talasemi Dayanışma Derneği